In this update we added a new drug monograph for DALBAVANCIN.
We added new stability information to the existing drug monographs for AMIODARONE HYDROCHLORIDE, CARBOPLATIN, CEFAZOLIN SODIUM, CEFTAZIDIME, INFLIXIMAB, MEROPENEM, METHOTRIMEPRAZINE HYDROCHLORIDE, PIPERACILLIN and TAZOBACTAM, AND SODIUM THIOSULFATE.
In addition, new compatibility information is reported for these drugs: ACETAMINOPHEN, AMPICILLIN SODIUM, AMPICILLIN SODIUM – SULBACTAM SODIUM, BLINATUMOMAB, CEFTAZIDIME, CLINDAMYCIN PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE, DOXORUBICIN HYDROCHLORIDE, ETOPOSIDE PHOSPHATE, FENTANYL CITRATE, FOSPHENYTOIN SODIUM, FUROSEMIDE, HALOPERIDOL LACTATE, HYDROMORPHONE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE, KETOPROFEN, LIDOCAINE HYDROCHLORIDE, MAGNESIUM SULFATE, METRONIDAZOLE HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE, RASBURICASE, SUGAMMADEX, TOTAL PARENTERAL NUTRITION SOLUTIONS, VINCRISTINE SULFATE, and VORICONAZOLE.